Phase 3b trial in 271 adults with active psoriatic arthritis and overweight or obesity: ixekizumab plus tirzepatide vs ixekizumab alone more often achieved ACR50 with ≥10% weight loss at 36 weeks (31.7% vs 0.8%; P<0.001). ACR50 alone 33.5% vs 20.4%.
RCTn = 271
Merola et al. Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial